Condition: Prostate Cancer · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant prostate cancer (mCRPC).
This description comes directly from the study's public registry record.
Wassim Abida, MD, PhD · 646-442-4633 · abidam@mskcc.org
Michael Morris, MD · 646-422-4469
Always discuss trial participation with your own doctor first.
| Yale University (Data Collection Only) | New Haven, Connecticut, United States | Recruiting |
| Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison, New York, United States | Recruiting |
| Columbia University | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale, New York, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Recruiting |
| Thomas Jefferson University Hospital | Philadelphia, Pennsylvania, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06457919